Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

First came the slow hand movements, then the tremor, and now the looming fear of what lies ahead. By the end of the decade, ...

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms ...

Neurological conditions are now the leading cause of ill health worldwide, yet remain an enigma. Meet the patients who baffle ...

In Episode 746 of Power Athlete Radio, Dr. Adeel Khan dives into cutting-edge advancements in regenerative medicine, focusing on induced pluripotent stem cells ...

The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose ...

Chantal Theriault is inviting the community to join her for the 2nd annual Kick it for Parkinson’s fundraiser at Therien ...

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Parkinson's disease is a solvable problem, but only if we act decisively and urgently. We have the knowledge, and we've built ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...